1. Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): protocol for identification of novel biomarkers via neurophysiology
- Author
-
Daskalakis, Zafiris J, McClintock, Shawn M, Hadas, Itay, Kallioniemi, Elisa, Zomorrodi, Reza, Throop, Alanah, Palmer, Lucy, Farzan, Faranak, Thorpe, Kevin E, Tamminga, Carol, and Blumberger, Daniel M
- Subjects
Clinical Trials and Supportive Activities ,Depression ,Neurodegenerative ,Neurosciences ,Clinical Research ,Serious Mental Illness ,Mental Health ,Behavioral and Social Science ,Suicide ,Brain Disorders ,Epilepsy ,Major Depressive Disorder ,6.6 Psychological and behavioural ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Mental health ,Biomarkers ,Depressive Disorder ,Treatment-Resistant ,Humans ,Neurophysiology ,Randomized Controlled Trials as Topic ,Seizures ,Treatment-resistant depression ,Magnetic seizure therapy ,Electroconvulsive therapy ,Transcranial magnetic stimulation ,Electroencephalography ,Cortical inhibition ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Cardiovascular System & Hematology ,General & Internal Medicine - Abstract
BackgroundElectroconvulsive therapy (ECT) is the most effective treatment for treatment-resistant depression (TRD), especially for acute suicidal ideation, but the associated cognitive adverse effects and negative stigma limit its use. Another seizure therapy under development is magnetic seizure therapy (MST), which could potentially overcome the restrictions associated with ECT with similar efficacy. The neurophysiological targets and mechanisms of seizure therapy, however, remain poorly understood.Methods/designThis neurophysiological study protocol is published as a companion to the overall Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) protocol that describes our two-site, double-blind, randomized, non-inferiority clinical trial to develop MST as an effective and safe treatment for TRD. Our aim for the neurophysiological component of the study is to evaluate two biomarkers, one to predict remission of suicidal ideation (primary outcome) and the other to predict cognitive impairment (secondary outcome). Suicidal ideation will be assessed through cortical inhibition, which according to our preliminary studies, correlates with remission of suicidal ideation. Cortical inhibition will be measured with simultaneous transcranial magnetic stimulation (TMS) and electroencephalography (EEG), TMS-EEG, which measures TMS-evoked EEG activity. Cognitive adverse effects associated with seizure therapy, on the contrary, will be evaluated via multiscale entropy analysis reflecting the complexity of ongoing resting-state EEG activity.DiscussionECT and MST are known to influence cortical inhibition associated with depression, suicidal ideation severity, and clinical outcome. Therefore, evaluating cortical inhibition and brain temporal dynamics will help understand the pathophysiology of depression and suicidal ideation and define new biological targets that could aid clinicians in diagnosing and selecting treatments. Resting-state EEG complexity was previously associated with the degree of cognitive side effects after a seizure therapy. This neurophysiological metric may help clinicians assess the risk for adverse effects caused by these useful and effective treatments.Trial registrationClinicalTrials.gov NCT03191058 . Registered on June 19, 2017.
- Published
- 2021